Immune Thrombocytopenia (ITP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Immune thrombocytopenia (ITP) is a disorder marked by low platelet count, which is crucial for blood clotting due to an autoimmune reaction. This condition manifests as visible skin discoloration caused by blood leaking beneath the skin's surface. Primary ITP arises from immune dysfunction, resulting in low platelet count (<100 × 10^9/L), driven by autoantibodies targeting platelets, T cell-mediated destruction of platelets, and impaired megakaryocyte function. It affects individuals of all ages and genders. In contrast, secondary ITP occurs due to underlying conditions, such as chronic infections (e.g., Helicobacter pylori, HIV) or autoimmune diseases (e.g., lupus, rheumatoid arthritis). In infectious cases, molecular mimicry may lead to the production of cross-reactive autoantibodies against platelets. The primary mechanism in ITP involves IgG autoantibodies binding to platelets and megakaryocytes, mainly targeting surface antigens like GPIIbIIIa and GPIb-IX-V. Phagocytes, primarily in the spleen, then clear these autoantibody-bound platelets. Additionally, autoantibodies can hinder megakaryocyte maturation or cause their destruction, contributing to decreased platelet production despite normal or reduced thrombopoietin levels (TPO). Treatment strategies for ITP range from inhibiting autoantibody production and platelet destruction as first-line options to immunosuppressive drugs like Rituximab and splenectomy as second-line approaches. Third-line treatments aim to boost platelet production from megakaryocytes.

·       In the USA, the annual incidence of ITP in adults is estimated at 3.3 per 100,000, with a prevalence of 9.5 cases per 100,000.

 

Thelansis’s “Immune Thrombocytopenia (ITP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Immune Thrombocytopenia (ITP) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Immune Thrombocytopenia (ITP) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Immune Thrombocytopenia (ITP) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Immune Thrombocytopenia (ITP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Immune Thrombocytopenia (ITP), Immune Thrombocytopenia (ITP) market outlook, Immune Thrombocytopenia (ITP) competitive landscape, Immune Thrombocytopenia (ITP) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)